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Abstract
Background: Hepatocellular carcinoma (HCC) is third leading cause of cancer-related death globally. Evidence
suggest that long non-coding RNAs (lncRNAs) have emerged as key regulators of tumorigenesis and metastasis in
HCC. In this study, we investigated the functional significance of SNHG12 and explored whether SNHG12 can
directly interact with miR-199a/b-5p in the progression of HCC.
Methods: We determined the expression level of SNHG12 in HCC tissues with quantitative real-time PCR and then
studied its clinical significance. The binding site between SNHG12 and miR-199a/b-5p was confirmed using dual
luciferase assay and RNA immunoprecipitation (RIP) assay. SNHG12 was silenced through the siRNA transfection to
determine whether SNHG12-siRNA is able to affect cell proliferation, invasion and metastasis.
Results: SNHG12 was significantly higher in the HCC tissues than that in the adjacent normal tissues. There were
direct interactions between miR-199a/b-5p and the binding site of SNHG12. SNHG12 functioned as an endogenous
sponge for miR-199a/b-5p to regulate the expression of MLK3 and affect the NF-κB pathway.
Conclusion: SNHG12 may serve as a valuable biomarker and a potential therapeutic target for HCC.
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Background
Hepatocellular carcinoma (HCC) has been deemed the
fifth most common type of malignant tumor. It has been
estimated that about 500,000 to 1,000,000 new cases are
diagnosed as HCC annually which has the third mortal-
ity rate among cancers [1]. Invasion, metastasis and
postoperative recurrence are regarded as the main
causes of death in patients with HCC. More seriously,
HCC is frequently diagnosed at an advanced stage and
therefore has a high lethality [2]. The molecular mech-
anism underlying HCC carcinogenesis has not been
clearly elucidated. The development and progression of
HCC are often described as a multistage process involv-
ing a series of genetic alterations that play the crucial
roles in the malignant transformation of the hepatocytes
[3]. Currently, an increasing number of studies reported
the role of non-coding RNAs (ncRNAs) in the carcino-
genesis of HCC, including micro-RNAs (miRNAs), long
non-coding RNA (lncRNAs) and small nucleolar RNAs
(snoRNAs) [4–6].
Long non-coding RNAs (lncRNAs) are a class of RNA
molecule that are over 200 nucleotides in length and do
not code for proteins but bear the ability to regulate the
gene expression [4]. Accumulating evidence showed that
lncRNAs have been identified to affect multiple bio-
logical regulatory processes, including development, dif-
ferentiation and carcinogenesis [7, 8]. Additionally, the
dysregulation of lncRNAs may be associated with the
development and metastasis of various types of cancer
[9]. For instance, the lncRNA metastasis-associated lung
adenocarcinoma transcript 1 (MALAT1) was found to
be overexpressed in numerous kinds of cancer cells, to
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regulate the cell proliferation and inhibit the cell cycle
[10]. A recent study demonstrated that the lncRNA small
nucleolar RNA host gene 12 (SNHG12) promotes cell
proliferation and migration by upregulating AMOT gene
expression in human osteosarcoma [11]. However, the
functional role and specific mechanism of SNHG12 in
HCC remain completely unclear. It is reported that all
RNA transcripts bearing miRNA-binding sites can interact
and regulate each other’s expression levels by specifically
competing for shared miRNAs, acting as competing
endogenous RNAs (ceRNAs) [12]. Emerging evidence
illustrated that this ceRNA regulation mode was con-
firmed in the various cancers [13, 14], indicating that there
are interactions between the lncRNAs and miRNAs in the
tumorigenesis [15, 16].
In the present study, we investigated the relationship
between SNHG12 and HCC, and found that SNHG12
was significantly overexpressed in HCC tissues as com-
pared with adjacent normal tissues, and this overex-
pression of SNHG12 was associated with substantially
declined survival of HCC patients. Furthermore, func-
tional analysis and bioinformatics prediction indicated
SNHG12 inhibited both cell proliferation and tumori-
genicity of HCC cells, possible by targeting miR-199a/
b-5p and then effects on NF-κB pathway.
Methods
Tissue specimens and cell lines
The paired HCC samples and the adjacent non-tumor tis-
sues were collected following curative surgical resection
from 48 patients with HCC in the Zhongnan Hospital of
Wuhan University between May 2011 and May 2013. The
present study was approved by the Hospital’s Protection
of Human Subjects Committee and written informed con-
sent was obtained from all patients. Based on their med-
ical documents, we conducted a 48-month follow up
survival survey. Overall survival (OS) was defined as the
interval between resection and death or the last follow-up
visit. Recurrence free survival (RFS) was defined as the
interval between treatment and the first diagnosis of me-
tastasis or recurrence. Curative resection was defined as
the removal of all recognizable tumor tissue with a clear
microscopic margin. Patients were not treated using any
preoperative therapy, such as transcatheter arterial che-
moembolization, radiofrequency ablation or percutaneous
ethanol injection. SK-Hep1 cell line included in this study
was purchased from the Cell Bank of Type Culture Col-
lection (CBTCC, Chinese Academy of Sciences, Shanghai,
China) and cultured in DMEM/high glucose medium (GE
Healthcare Life Sciences HyClone Laboratories, Logan,
USA) supplemented with 10% fetal bovine serum (FBS;
Gibco; Thermo Fisher Scientific, Inc., Waltham, MA,
USA) and 1% penicillin and streptomycin in a humidified
atmosphere of 5% CO2 at 37 °C.
In situ hybridization (ISH)
ISH was used to detect SNHG12 in 48 paired of HCC
samples. A digoxigenin-UTP-labeled antisense RNA probe
(Beijing View Solid Biotechnology) was derived from 28 to
257 nt of SNHG12 by in vitro transcription using the DIG
RNA Labeling kit (Roche Diagnostics, Indianapolis, IN,
USA). The digoxigenin-UTP labeled sense RNA probe de-
rived from 28 to 257 nt of SNHG12 was used as a negative
control. ISH was performed using the ISH kit (Boster Bio-
Engineering Company, Wuhan, China).
RNA extraction and quantitative real-time PCR
Total RNA was extracted from clinical HCC specimens
and human HCC cell lines in Trizol reagent kit (Invitrogen,
Carlsbad, CA, USA), according to the manufacturer’s in-
structions. RNA concentration was measured by using a
NanoDrop ND-2000 spectrophotometer (Life Technolo-
gies). Reverse transcription was conducted with random
primers using the First Strand cDNA synthesis kit (Takara,
Otsu, Shiga, Japan). Real-time quantitative PCR was
performed with an iQ SYBR-Green Supermix (Bio-Rad,
California, USA). All reactions were run in triplicate
on the iCycler IQ multi-color Detection System (Bio-
Rad, California, USA). The amplification profile was dena-
tured at 95 °C for 10 min, followed by 45 cycles of denatur-
ation at 95 °C for 20 s, annealing at 60 °C for 20 s and
extension at 72 °C for 20 s. The comparative cycle thresh-
old (CT) method was applied to quantify the expression
levels of mRNA. The relative amount was calculated using
the equation 2 −ΔCT where ΔCT= (CT interest mRNA –
CT U6). All qPCR reactions were performed in duplicate.
Primers used in this study are listed in Table 1.
RNA interference and cell transfection
The small interfering RNA (siRNA) targeting SNHG12
was obtained from Sigma-Aldrich (Sigma, USA), and the
miR-199a/b-5p mimic was synthesized by Genepharma
(Shanghai, China). SK-Hep1 cells were transfected with
50 nM miR-199a/b-5p mimic using Lipofectamine 2000
(Invitrogen Co., Carlsbad, CA, USA) and transfected
with 100 nM SNHG12-siRNA using GenMute (Signa-
Gen Laboratories, Rockville, MD, USA) according to the
manufacturer’s protocol. After transfection, cells were
harvested for qPCR analysis or western blot.
Protein extraction and western blot
Total proteins were extracted with RIPA Lysate Buffer
(Beyotime Institute of Biotechnology, Shanghai, China),
separated by 10% SDS-PAGE and transferred onto PVDF
membranes. Subsequently, the PVDF membrane was
blocked with 5% skim milk powder in TBST (10 mM
Tris–HCl, pH 7.5, 150 mM NaCl, and 0.1% Tween-20) at
room temperature for 2 h. Then, the primary antibodies
were added and incubated overnight at 4 °C. After
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washing with TBST buffer, the HRP-labeled antibody
(Proteintech Group, Inc., Chicago, IL, USA; 1:4000 dilu-
tion) was added and the membrane was incubated at RT
for 2 h. The proteins were visualized by autoradiography
using the ECL chemiluminescence reagent (Bio-Rad,
California, USA). The relative expression of interest pro-
tein was represented as the grayscale ratio of the protein
to GAPDH and the results were analyzed by GraphPad
Prism 5.0 software. The information of antibodies used in
this study was presented in Table 2.
Cell proliferation assay
A total of 3 × 104 cells were seeded in each well of a 96-
well plate, and incubated for 24 h. Ten Microliter WST-
8 from the CCK-8 Kit (Boster, Wuhan, China) was then
added to each well. After incubation at 37 °C in 5% CO2
for 12, 24, 48, 72 and 96 h, the absorbance of each sam-
ple was measured at a wavelength of 450 nm by using
the Thermo Plate microplate reader (Rayto Life and
Analytical Science Co. Ltd., Germany).
Flow cytometry analysis
Cell apoptosis was tested by two-color immunofluores-
cence staining in the flow cytometric analysis. Cells were
trypsinized without EDTA followed by two washing
steps with phosphate buffered saline. 2 × 105 cells per
well were then incubated with 5 μl of FITC Annexin V
(BD Pharmingen) and 5 μl of propidium iodide (BD
Table 1 Primer sequences for qPCR
Gene Primer Sequence
SNHG12 Forward primer 5′-TCTGGTGATCGAGGACTTCC-3′
Reverse primer 5′-ACCTCCTCAGTATCACACACT-3′
miR-199a-5p Stem-loop primer 5′-ctcaactggtgtcgtggagtcggcaattcagttgagGAACAGG-3′
Forward primer 5′-acactccagctgggCCCAGT-3′
miR-199b-5p Stem-loop primer 5′-ctcaactggtgtcgtggagtcggcaattcagttgagGAACAGA-3′
Forward primer 5′-acactccagctgggCCCAGT-3′
Reverse primer 5′-TGGTGTCGTGGAGTCG-3′
U6 Forward primer 5′-GCTTCGGCAGCACATATACTAAAAT-3′
Reverse primer 5′-CGCTTCACGAATTTGCGTGTCAT-3′
SNORA44 Forward primer 5′-CTCCAACTGCATGCAAGAGC-3′
Reverse primer 5′-ATAGGAAAGCTGAGTGGCAGC-3′
SNORA61 Forward primer 5′-CACTGGTCTTGGTGGTCGTAA-3′
Reverse primer 5′-ACCTGTCTGAAACTAGCCCAC-3′
SNORA16A Forward primer 5′-CTGCTGTGGTCAAAAAGGAGC-3′
Reverse primer 5′-TCAGTTACAACAAACAGAACGGC-3′
SNORD99 Forward primer 5′-ACTGGTCCAGGATGAAACCTA-3′
Reverse primer 5′-GGTCTCAGTCCCATATCCGC-3′
Table 2 Antibody information used in this study





anti-GAPDH polyclonal rabbit anti-human 1/4000 10494-1-AP Proteintech Group, Inc., Chicago, IL, USA
anti-MLK3 monoclonal rabbit anti-human 1/5000 ab51068 Abcam, Cambridge, MA, USA
anti-IκB-α monoclonal rabbit anti-human 1/2000 ab32518 Abcam, Cambridge, MA, USA
anti-pIκB-α monoclonal rabbit anti-human 1/2000 ab92700 Abcam, Cambridge, MA, USA
anti-NF-κB/p65 polyclonal rabbit anti-human 1/2000 ab16502 Abcam, Cambridge, MA, USA
anti-pNF-κB/p65 polyclonal rabbit anti-human 1/2000 ab86299 Abcam, Cambridge, MA, USA
anti-Erk1/2 monoclonal rabbit anti-human 1/1000 4695S Cell Signaling Technology, Danvers, MA, USA
anti-pErk1/2 monoclonal rabbit anti-human 1/1000 4376S Cell Signaling Technology, Danvers, MA, USA
anti-Ago2 polyclonal rabbit anti-human ab32381 Abcam, Cambridge, MA, USA
HRP-conjugated secondary antibody goat anti-mouse 1/4000 SA00001-1 Proteintech Group, Inc., Chicago, IL, USA
goat anti-rabbit 1/4000 SA00001-2 Proteintech Group, Inc., Chicago, IL, USA
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Pharmingen) in 400 μl of 1 × binding buffer for 15 min
at room temperature. Data were analyzed by flow cytom-
etry (FACScan®; BD Biosciences, San Jose, CA) equipped
with CellQuest software (BD Biosciences).
Cell invasion assay
Transwell chambers were precoated with 200 μg/ml
Matrigel (BD Biosciences, San Jose, CA, USA) and
incubated overnight. SK-Hep1 cells were cultured in
serum-free medium in the upper chambers of a Transwell
(Corning, NY, USA) plate, which are separated from the
lower chambers with permeable 8.0 μm polycarbonate
membranes. The lower chamber was filled with 500 μL
DMEM containing 10% FBS. After incubation for 24 h,
the cells remaining on the upper membrane were carefully
removed, the others that had invaded through the mem-
brane were fixed with 4% paraformaldehyde and stained
with 0.1% crystal violet. The number of stained cells were
manually counted under a phase contrast microscope
from three different visual fields of each filters.
Cell migration assay
Cells were cultured in 6-well plates (seeding density 1 ×
106 cells/well). Confluent cell monolayers was disrupted
by standardized wound scratching using a sterile 10 μL
pipette tip and incubated in serum-free medium. The
size of the wound was measured after 24 h of wound
formation and photographed by using a phase contrast
microscope.
Construction of the recombinant plasmid
The full-length SNHG12 was amplified by PCR, and the
PCR products were digested and ligated into pMir-
Reporter plasmid (Ambion, Life Technologies, Carlsbad,
CA, USA). The miR-199a/b-5p binding site mutations
were generated using a QuikChange Multi Site-Directed
Mutagenesis Kit (Stratagene, La Jolla, CA, USA). The in-
sertion and mutation were verified using sequencing.
Dual luciferase assay
Cells were cultured overnight until 60–70% confluence.
Next, cells were co-transfected with pMir-Reporter-
SNHG12-WT or pMir-Reporter-SNHG12-MUT and
miR-199a/b-5p mimic. Lipofectamine 2000 (Invitrogen
Co., Carlsbad, CA, USA) was used according to the
manufacturer’s instructions. After 48 h, cells were har-
vested for luciferase detection using the dual-luciferase
reporter gene assay system (Promega, Madison, WI,
USA). All values were obtained from at least three inde-
pendent repetitions of the transfection.
RNA immunoprecipitation (RIP) assay
RIP assay was performed using the Magna RIPTM RNA-
Binding Protein Immunoprecipitation Kit (Millipore,
Bedford, MA, USA) according to the manufacturer’s
protocol. Cells at 80–90% confluence were collected and
were lysed using RIP lysis buffer. Next, the cell extracts
were incubated with RIP buffer containing magnetic beads
conjugated with human anti-Ago2 antibody or negative
control IgG. The samples were incubated with Proteinase
K to digest the protein and subsequently the precipitated
RNA was obtained. The purified RNA was finally used for
qPCR analysis of SNHG12 and miR-199a/b-5p.
ChIRP assay
17 oligonucleotide probes corresponding to the SNHG12
transcript were produced by using the Stellaris Probe De-
signer (https://www.biosearchtech.com/stellarisdesigner/).
The oligonucleotide sequences (Presented in Table 3) were
synthesized with an 18-atom spacer followed by a biotin
tag located at the 3′ end, according to the manufacturer
(IDT, Coralville, Iowa). The autopod regions of the E 11
limbs were dissected and digested in PBS containing 0.1%
trypsin and 0.1% collagenase for 15 mins. Then, cell lysis
and streptavidin bead precipitation were completed utiliz-
ing a Bioruptor instrument (Diagenode). Cells with
SNHG12-WT and SNHG12-MUT were used in parallel
assays. The precipitated RNA was identified and quanti-
fied by using RT-qPCR. The relative amount was calcu-
lated using the equation 2 −ΔCT where ΔCT = (CT miR-
199a/b-5p – CT SNHG12). All qPCR reactions were per-
formed in duplicate.
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Statistical analysis
All experiments were performed in triplicate and data
were presented as mean ± SD. All statistical analyses
were performed with SPSS version 22.0 software (IBM,
Chicago, IL, USA). The expression level of SNHG12 in
HCC samples was compared with adjacent normal tis-
sues utilizing the paired sample t-test. The association
between SNHG12 expression and clinicopathological
variables was evaluated using the chi-square test or Fish-
er’s exact test. The Kaplan-Meier test was used to esti-
mate OS and RFS. The expression differences between
groups, the expression changes after transfection, cell
viability and cell invasion assays were analyzed using in-
dependent samples t-test or one-way analysis of variance
(ANOVA). A value of P < 0.05 was considered to be sta-
tistically significant.
Results
SNHG12 was strongly overexpressed in HCC tissues and
significantly associated with clinicopathological variables
and prognosis after surgery
To determine whether there was a difference of SNHG12
expression between HCC tissues and the adjacent normal
tissues, we detected the SNHG12 expression in 48 paired
specimens utilizing the qPCR (Fig. 1a and b). The expres-
sion of SNHG12 was significantly overexpressed in can-
cerous tissues (P < 0.001; Fig. 1c and d). Furthermore, in
order to assess the correlation between SNHG12 expres-
sion and clinicopathological variables, patients were di-
vided into the high expression group (n = 24) and the low
expression group (n = 24), based on the median expression
level of all tumor tissues. Specifically, as presented in
Table 4, SNHG12 expression levels in HCC were signifi-
cantly associated with tumor size (P < 0.05), vascular inva-
sion (P < 0.05), and TNM stage (P < 0.05). However,
SNHG12 expression was not correlated with other clinico-
pathological variables such as gender, age, serum AFP,
liver cirrhosis, PVTT and differentiation (P > 0.05). Be-
sides, HCC patients with high SNHG12 expression have
significantly shorter overall survival (P = 0.045; Fig. 1e)
and statistically higher recurrence rate (P = 0.019; Fig. 1f)
than those with low expression of SNHG12. These find-
ings illustrated that the overexpression of SNHG12 may
be associated with tumorigenesis and poor prognosis in
patients with HCC.
Knockdown of SNHG12 suppressed HCC cell proliferation
and induces cell apoptosis in vitro
To investigate the role of SNHG12 on HCC cell prolifer-
ation, SNHG12-siRNA was transfected into SK-Hep1
and HCCLM9 cells. Next, both two cell lines were di-
vided into two treatment groups: the SNHG12-siRNA
transfected group and the NC-siRNA group. The knock-
down effect of SNHG12 was confirmed by qPCR assay
Fig. 1 SNHG12 was overexpressed in HCC tissues and was associated with prognosis after surgery. a and b Relative SNHG12 expression in HCC tissues
(n = 48) compared with adjacent normal tissues (n= 48). SNHG12 expression was examined by qPCR and normalized to U6 expression. Results were
presented as ΔCT in tumor tissues relative to normal tissues. c and d SNHG12 expression was higher in HCC tissues compared with the paired adjacent
normal tissues. Data are presented as the mean ± standard error of the mean (n = 3). Kaplan-Meier analysis of (e) overall survival and (f) recurrence-free
survival based on SNHG12 expression levels in 48 patients with HCC. The median level of SNHG12 was used as the cut off. Patients with HCC were
divided into high SNHG12 expression group and low SNHG12 expression group. *P< 0.05
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which revealed that the SNHG12 expressions in SK-Hep1
and HCCLM9 cells of the SNHG12-siRNA transfected
group were significantly decreased by approximately 70%
(P < 0.05; Fig. 2a). Therefore, the interference ability of
siRNA for SNHG12 was effective and specific. Then, the
CCK-8 assay showed that the proliferation abilities of both
SK-Hep1 and HCCLM9 cells presented statistical decline
after knockdown of SNHG12 (P < 0.05; Fig. 2b and c).
Subsequently, flow cytometry analysis was performed to
further examine the effect of SNHG12 on the apoptosis of
SK-Hep1 and HCCLM9 cells, indicating that the
proportion of cells in early apoptosis witnessed a remark-
able upward trend by the silencing of SNHG12 (P < 0.05;
Fig. 2d and e).
Effects of SNHG12 interfering on HCC cell invasion and
migration in vitro
Cell invasion and migration assays were performed to de-
termine how SNHG12 affected these characteristics in SK-
Hep1 and HCCLM9 cells. The transwell chamber assay
suggested that the numbers of SK-Hep1 and HCCLM9
cells that had passed through the polycarbonate membrane
of the chamber were significantly reduced in the SNHG12-
siRNA transfected group (P < 0.05; Fig. 2f and g). The
wound-healing assay was conducted to investigate the
migration abilities of SK-Hep1 and HCCLM9 cells in these
two treatment groups. It was determined that the mi-
gration ability of cells in the SNHG12-siRNA trans-
fected group presented a significantly decrease, 24 h
after wounding (P < 0.05; Fig. 2h and i). These findings
demonstrated that the downregulation of SNHG12
weakened the migration and invasion abilities of SK-
Hep1 and HCCLM9 cells.
SNHG12 regulated HCC tumorigenesis and metastasis by
targeting miR-199a/b-5p and affected the NF-κB pathway
Since SNHG12 is the host gene of four small nucleolar
RNAs (snoRNAs): SNORA44, SNORA61, SNORA16A
and SNORD99, we hypothesized that SNHG12 might
exert its oncogenic function via these snoRNAs, and
thus we detected the effect of SNHG12 on their expres-
sions by using RT-qPCR. The data showed that knocking
down SNHG12 did not impact the snoRNAs expression
(Fig. 3a). To address the regulatory mechanism of
SNHG12 in HCC cell proliferation and invasion, we
firstly conducted the ISH assay to determine its subcel-
lular localization. The results showed that SNHG12 was
primarily located in the cytoplasm (Fig. 3b). Next, bioinfor-
matics prediction of miRcode (http://www.mircode.org/)
software suggested that there was putative binding sites
between SNHG12 and miR-199a/b-5p (Fig. 3c). As miR-
199a-5p and miR-199b-5p have the same seed sequence
and their functions in tumorigenesis are almost identical
[17–19], we selected miR-199a-5p as the study object to
analyze whether its expression was regulated by SNHG12.
By performing qPCR in all the 48 paired HCC samples
and the adjacent normal tissues, we verified signifi-
cantly lower miR-199a-5p expression in the tumor tis-
sues (Fig. 3d and e). Intriguingly, an inverse correlation
was found between SNHG12 and miR-199a-5p expres-
sion levels in 48 pairs of HCC tissues (Fig. 3f ). Subse-
quently, in order to verify the influence of SNHG12 on
miR-199a/b-5p expression, SK-Hep1 cells were trans-
fected with SNHG12-siRNA. The cells with SNHG12
knockdown did not present significantly changed miR-
199a/b-5p expression (Fig. 3g), which suggested that
SNHG12 could not impact the expression of miR-199a/
b-5p in HCC. Recent study has shown that decrement
of miR-199a-5p contributes to the tumorigenesis by
Table 4 Correlation between SNHG12 expression and
clinicopathological variables of HCC patients
Variable Total no.
(n = 48)
Relative SNHG12 expression P value
High (n = 24) Low (n = 24)
Gender
Male 37 19 18 0.7313
Female 11 5 6
Age (years)
<60 23 10 13 0.3861
≥60 25 14 11
Tumor size (cm)
<5 20 6 14 0.0192*
≥5 28 18 10
Serum AFP (ng/ml)
<200 9 4 5 1.0000
≥200 39 20 19
Liver cirrhosis
Present 25 15 10 0.1486
Absent 23 9 14
Vascular invasion
Present 23 16 7 0.0093*
Absent 25 8 17
PVTT
Present 8 5 3 0.7008
Absent 40 19 21
Differentiation
Well 7 4 3 0.6327
Moderate 33 15 18
Poor 8 5 3
TNM stage
I–II 22 7 15 0.0415*
III–IV 26 17 9
Abbreviation: AFP α-fetoprotein, PVTT, portal vein tumor thrombus,
TNM tumor-node-metastasis
* P < 0.05
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directly regulating MLK3/IkB/NF-κB pathway [20].
Likewise, MLK3 was proved to be the target gene of
miR-199b-5p and was directly regulated by miR-199b-
5p [21]. According to the previous prediction and the
ceRNA regulation mode, we speculated that SNHG12
was able to regulate the MLK3/IκB/NF-κB pathway. To
confirm that, the key molecules in the NF-κB pathway
(MLK3, IκB-α and NF-κB/p65) were detected by west-
ern blot. As shown in Fig. 3h and i, both elevated ex-
pression of miR-199a-5p and knockdown of SNHG12
suppressed the expression of MLK3 and the phos-
phorylation of IκB-α and NF-κB/p65 in SK-Hep1
cells. By contrast, the phosphorylation of Erk1/2, a
key regulator of MAPK signaling pathway, was not af-
fected. These results indicated that the MLK3/IκB/
NF-κB pathway may be involved in tumorigenesis in-
duced by SNHG12.
SNHG12 directly interacted with miR-199a/b-5p and
served as its sponge
To determine whether there were direct interactions be-
tween SNHG12 and miR-199a/b-5p, the full-length
SNHG12 was amplified by PCR, and the PCR products
were digested and ligated into pMir-Reporter plasmid
named pMir-Reporter-SNHG12-WT. Similarly, the mu-
tant construct without the putative binding site was also
generated and termed pMir-Reporter-SNHG12-MUT.
The plasmids were respectively transfected into SK-
Hep1 cells together with miR-199a/b-5p mimic or the
negative control. The data revealed that luciferase activ-
ity of pMir-Reporter-SNHG12-WT was significantly re-
duced by miR-199a/b-5p mimic (Fig. 4a). In contrast,
the luciferase activity of pMir-Reporter-SNHG12-MUT
experienced no statistical changes (Fig. 4a). These find-
ings indicated that there were interactions between miR-
Fig. 2 The functional analysis of SNHG12 in HCC cells. a The SNHG12 expression level was determined by qPCR when SK-Hep1 and HCCLM9 cells
were transfected with SNHG12-siRNA. b CCK-8 assay was applied to detect the proliferation of SK-Hep1 cells. c CCK-8 assay was applied to detect
the proliferation of HCCLM9 cells. d and e Flow cytometry assays were performed to analyze the apoptosis of SK-Hep1 and HCCLM9 cells after treatment
with SNHG12-siRNA and stained with apoptosis markers (FITC-Annexin V and PI). f and g The ability of cancer cell invasion was measured by using
transwell assay when SNHG12 was downregulated in SK-Hep1 and HCCLM9 cells [original magnification, ×250 and × 100]. h and i The ability of cancer
cell migration was measured by using wound-healing assay when SNHG12 was downregulated in SK-Hep1 and HCCLM9 cells [original magnification,
×100]. Data represented the mean ± SD from three independent experiments. *P < 0.05; NS: no significance
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199a/b-5p and the binding sites of SNHG12. In addition,
we found that the sites could also bind the Argonaute 2
(Ago2) protein, according to the prediction in StarBase
v2.0 (http://starbase.sysu.edu.cn/mirLncRNA.php) (Fig. 4b).
Previous study showed that miRNAs exert their gene si-
lencing functions via RNA-induced silencing complex
(RISC) containing Ago2 [22]. Emerging evidence demon-
strated that lncRNAs might act as the sponge of miRNAs
and function through binding the miRNAs and Ago2 [14].
Thus, we hypothesized that SNHG12 and miR-199a/b-5p
might interact in the same way. To verify the speculation,
RNA binding protein immunoprecipitation (RIP) assay
was performed in SK-Hep1 cell extracts utilizing the anti-
body against Ago2. The levels of SNHG12 and miR-199a/
b-5p were detected by qPCR. The results illustrated that
both SNHG12 and miR-199a/b-5p were statistically
enriched in Ago2 pellet relative to control IgG
immunoprecipitates (Fig. 4c), indicating that Ago2 could
directly bind the SNHG12 and miR-199a/b-5p in SK-
Hep1 cells. Furthermore, we performed the ChIRP assays
to demonstrate the direct interactions between SNHG12
and the miR-199a/b-5p. The data revealed that SNHG12-
WT could be immunoprecipitated with miR-199a/b-5p.
However, the SNHG12 with mutated binding site abol-
ished the interaction (Fig. 4d), indicating that both miR-
199a-5p and miR-199b-5p could directly bind to SNHG12
via a miRNA recognition site. Together, our results
suggested that SNHG12 served as a sponge for miR-199a/
b-5p and its oncogenic function greatly depended upon
miR-199a/b-5p.
Discussion
Growing study reported that ncRNAs have been identi-
fied to be dysregulated in a wide range of physiological
Fig. 3 SNHG12 regulated the expression of miR-199a/b-5p target gene and affected the NF-κB pathway. a The expressions of related snoRNAs were
determined by qPCR when SK-Hep1 cells were transfected with SNHG12-siRNA. b Representative images of SNHG12 expression in human HCC tissues
and adjacent non-tumor tissues by ISH assays. c Predict binding sites between SNHG12 and miR-199a/b-5p. d and e The expression of miR-199a-5p was
lower in HCC tissues compared with the paired adjacent normal tissues by qPCR. f Bivariate correlation analysis of the negative association between
SNHG12 expression level and miR-199a-5p expression level in 48 pairs of HCC tissues. g The miR-199a/b-5p expression level was determined by qPCR
when SK-Hep1 cells were transfected with SNHG12-siRNA. h and i Western blot analysis of key molecules in NF-κB pathway after SNHG12 knockdown
or miR-199a-5p overexpression in SK-Hep1 cells. Relative protein expression was identified and normalized to GAPDH. Data represented the mean ± SD
from three independent experiments. *P < 0.05; NS: no significance
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and pathological processes, as well as malignant diseases
[23, 24]. A number of studies have indicated the role of
lncRNAs in cancer progression and predicts patients’
outcome [7, 10].
In this study, we systematically investigated potential role
of oncogenic lncRNA SNHG12 and provided first evidence
of SNHG12 dysregulation in HCC. Our results showed that
the expression of SNHG12 in HCC tissues was significantly
higher than that in adjacent normal tissues and it was
remarkably associated with tumor size (P < 0.05), vascular
invasion (P < 0.05), and TNM stage (P < 0.05). Additionally,
based on the 48-month follow-up survival survey, our find-
ings revealed that HCC patients with high SNHG12 expres-
sion have poorer OS and DFS than those with low
expression of SNHG12 (P < 0.05, respectively), suggesting
that SNHG12 could be regarded as a prognostic factor for
HCC. Next, we determined the in vitro functional signifi-
cance of SNHG12 in HCC cell lines via RNA interference.
The data demonstrated that SNHG12 silencing inhibited
cell proliferation by inducing cell apoptosis. Furthermore,
the abilities of invasion and migration have been suppressed
by the knockdown of SNHG12.
We observed an inverse correlation between SNHG12
and miR-199a-5p, which stimulated our interest to deter-
mine whether there was a ceRNA mechanism involved be-
tween SNHG12 and miR-199a/b-5p. To begin with, we
performed the bioinformatics analysis to seek putative
binding sites between them. Following that, it was proved
that miR-199a/b-5p could bind the SNHG12 by conduct-
ing the dual luciferase assay. Most importantly, we found
an endogenous interaction between SNHG12 and miR-
199a/b-5p by utilizing co-immunoprecipitation with the
Fig. 4 SNHG12 directly interacted with miR-199a/b-5p and served as a sponge. a Wild type and mutant SNHG12 sequences were cloned into
pMir-Reporter vectors and co-transfected with miR-199a/b-5p mimic or miR-NC into SK-Hep1 cells. The relative luciferase activity was normalized
with renilla luciferase activity. b Use of the StarBase and miRcode databases showed that the putative binding sites for both miR-199a/b-5p and
the Ago2 protein at SNHG12 is highly conserved in human, rhesus, mouse, dog and elephant. c RNA immunoprecipitation with the anti-Ago2
antibody was used to assess endogenous Ago2 binding to RNA. The levels of SNHG12 and miR-199a/b-5p were detected by qPCR. d ChIRP assay
followed by RT-qPCR to detect miR-199a/b-5p. e and f SNHG12 functioned as a sponge for miR-199a/b-5p and activated the NF-κB pathway
which promoted the tumorigenesis in HCC. Data represented the mean ± SD from three independent experiments. *P < 0.05; NS: no significance
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Ago2 antibody in SK-Hep1 cells. Subsequently, ChIRP
assays demonstrated that there were direct interactions
between SNHG12 and the miR-199a/b-5p. Eventually,
SNHG12 was able to modulate the expression of the miR-
199a/b-5p target gene, MLK3, and thus affected the NF-
κB pathway. Overall, these results demonstrated that
SNHG12 could act as an endogenous sponge, or ceRNA,
to regulate miR-199a/b-5p availability for the target gene.
Mixed-lineage protein kinase 3 (MLK3) is a member of
the mitogen-activated protein (MAP) kinase group which
plays a crucial role in multiple signaling cascades, includ-
ing the NF-κB pathway [25]. The expression of MLK3 was
upregulated in tumor tissues and was associated with
tumor progression and metastasis [26]. Based on our pre-
vious work, we designed a sponge model including
SNHG12 and miR-199a/b-5p in HCC (Fig. 4e and f).
Conclusion
In conclusion, the current study revealed that SNHG12
may be required for tumorigenesis and has the potential
to be developed as a clinically promising biomarker for
malignant phenotype of HCC. Furthermore, SNHG12
was found to function as a sponge for miR-199a/b-5p to
reduce the inhibiting effect on MLK3, and thus en-
hanced the expressions of MLK3 and its downstream ef-
fectors in the NF-κB pathway.
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